Surmodics, Inc. SRDX is well-poised for growth in the coming quarters, courtesy of its solid prospects in the thrombectomy business over the past few months. The optimism led by a solid second-quarter ...
Surmodics, a maker of medical device coatings and diagnostics components, has agreed to sell to a private equity firm for approximately $627 million. \r GTCR will acquire the company for $43 per share ...
Surmodics makes coatings for medical devices and manufactures chemicals for diagnostic immunoassay tests. On Wednesday morning, before the markets opened, the healthcare company announced that the FDA ...
Shares of SurModics (SRDX) have been on an upswing since reporting a solid fiscal third quarter in early August, and recently hit its 52-week high of $22.21 on October 5. With a year-to-date return of ...
Surmodics (NASDAQ:SRDX) is set to give its latest quarterly earnings report on Wednesday, 2025-04-30. Here's what investors need to know before the announcement. Analysts estimate that Surmodics will ...
EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Surmodics, Inc. (NASDAQ: SRDX), the global leader in medical device coating technologies, announced the commercial launch of its most advanced hydrophilic medical ...
EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--SurModics, Inc. (Nasdaq: SRDX), a leading provider of drug delivery and surface modification technologies to the healthcare industry, announced today certain ...
SurModics (SRDX) is a leading provider of surface modification technologies in the areas of biocompatibility, site specific drug delivery, biological cell encapsulation, and medical diagnostics.
As proxy fights go, the battle for SurModics Inc. (NASDAQ:SRDX), based in Eden Prairie, is downright tame — for now. Last week, Ramius LLC, the alternative investment firm of Cowen & Co. that recently ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results